These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 31138700)
1. Photocontrollable mononegaviruses. Tahara M; Takishima Y; Miyamoto S; Nakatsu Y; Someya K; Sato M; Tani K; Takeda M Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11587-11589. PubMed ID: 31138700 [TBL] [Abstract][Full Text] [Related]
2. Optical Control of Mononegavirus Gene Expression and Replication. Tahara M; Okura T; Sato M; Takeda M Methods Mol Biol; 2024; 2808():35-56. PubMed ID: 38743361 [TBL] [Abstract][Full Text] [Related]
3. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145 [TBL] [Abstract][Full Text] [Related]
4. Oncolytic measles virus retargeting by ligand display. Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression. Robinson M; Ge Y; Ko D; Yendluri S; Laflamme G; Hawkins L; Jooss K Cancer Gene Ther; 2008 Jan; 15(1):9-17. PubMed ID: 17853920 [TBL] [Abstract][Full Text] [Related]
10. Measles virus as an oncolytic vector platform. Blechacz B; Russell SJ Curr Gene Ther; 2008 Jun; 8(3):162-75. PubMed ID: 18537591 [TBL] [Abstract][Full Text] [Related]
11. Generation of recombinant measles virus containing the wild-type P gene to improve its oncolytic efficiency. Alizadeh R; Ghanei M; Arashkia A; Dorostkar R; Azadmanesh K Microb Pathog; 2019 Oct; 135():103631. PubMed ID: 31381964 [No Abstract] [Full Text] [Related]
13. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768 [TBL] [Abstract][Full Text] [Related]
14. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma. Zhang SC; Wang WL; Cai WS; Jiang KL; Yuan ZW BMC Cancer; 2012 Sep; 12():427. PubMed ID: 23009685 [TBL] [Abstract][Full Text] [Related]
15. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533 [TBL] [Abstract][Full Text] [Related]
16. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Dispenzieri A; Tong C; LaPlant B; Lacy MQ; Laumann K; Dingli D; Zhou Y; Federspiel MJ; Gertz MA; Hayman S; Buadi F; O'Connor M; Lowe VJ; Peng KW; Russell SJ Leukemia; 2017 Dec; 31(12):2791-2798. PubMed ID: 28439108 [TBL] [Abstract][Full Text] [Related]
17. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872 [TBL] [Abstract][Full Text] [Related]
19. Advance in herpes simplex viruses for cancer therapy. Liu S; Dai M; You L; Zhao Y Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184 [TBL] [Abstract][Full Text] [Related]